Carregant...
Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice
BACKGROUND: Nalfurafine is the first clinically approved kappa-opioid receptor (KOP-r) agonist as an anti-pruritus drug with few side effects in humans (e.g., sedation, depression and dysphoria). No study, however, has been done using nalfurafine on alcohol drinking in rodents or humans. METHODS: We...
Guardat en:
| Publicat a: | Alcohol Clin Exp Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551307/ https://ncbi.nlm.nih.gov/pubmed/30908671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acer.14033 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|